A Phase I-II Study of Systemic Capecitabine, Cisplatin and Intraperitoneal Docetaxel (XPID) in Patients With Advanced Stomach Cancer With Peritoneal Seeding
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary) ; Bevacizumab; Capecitabine; Cisplatin
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClincialTrials.gov.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 22 Apr 2013 Planned end date changed from 1 Jul 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.